The week of April 21 arrives with two major CMS actions already in motion: the CY 2027 Medicare Advantage & Part D Final Rule published April 6 and the end of the price transparency enforcement grace period on April 1. Both carry direct implications for practices billing Medicare Advantage and hospital outpatient services.
CMS issued the final rule on April 2 and published it in the Federal Register on April 6, governing Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year 2027. The rule takes effect June 1, 2026, with most coverage provisions applying January 1, 2027, and marketing/communications changes effective October 1, 2026.
CMS released the April 2026 ICD-10-CM quarterly update with no code additions, deletions, or revisions — but 14 chapters now contain revised instructional notes effective April 1. The most practice-impacting change: several Excludes1 notes have been converted to Excludes2, including under D18 (Hemangioma and lymphangioma, any site) and D49 (Neoplasms of unspecified behavior).
This distinction matters operationally. An Excludes1 note means codes cannot be used together — an Excludes2 note means codes can be coded simultaneously when both conditions are present. Code pairs that were invalid before April 1 may now be legitimately billable together, creating new documentation and coding opportunities — and new audit risk if misapplied.
The removal of 11 Star Ratings measures focused on administrative processes and provider complaints is a meaningful shift for practices. Plans will no longer be scored on how they handle provider appeals and complaints — reducing the financial incentive for payers to resolve provider disputes quickly. Expect MA plan dispute resolution timelines to lengthen in the 2027 contract year as the Star Ratings performance pressure on these categories evaporates.
In June 2025, over 60 major health insurers — including UnitedHealthcare, Aetna, Cigna, Humana, Elevance Health, and the Blue Cross Blue Shield Association — pledged sweeping prior authorization reforms with 2026 and 2027 timelines. AHIP’s spokesperson Chris Bond confirmed the first public progress report will be released in spring 2026 — it is due now. Here is where the major payers stand as of April 2026.
| Payer | Electronic Standardization | PA Volume Reduction | Real-Time Tools |
|---|---|---|---|
| Aetna | 88% of PA volume standardized | “Fewest medical services requiring PA” among national plans; bundled procedure + drug into single PA submission | Yes |
| UnitedHealthcare | >50% standardized; targeting >70% by EOY 2026 | 231 procedures removed Dec. 2025 (nuclear medicine, OB ultrasounds, ECGs) | In progress |
| Cigna | Targeting >70% by EOY 2026 on rolling basis | ~100 services eliminated; real-time PA status tools added; expanded patient support teams | Yes |
| All 50+ Plans | — | Honor existing authorizations 90 days when patient switches plans; standardized denial explanations & appeal options | Varies |
Despite the voluntary reform commitments, denial data tells a more complicated story. Medicare Advantage denial rates remain at approximately 17% — more than double traditional Medicare’s ~8%. PA appeal reversal rates remain stubbornly high at 80.7%, meaning roughly four out of five MA PA denials that are appealed are ultimately overturned. If denials were being issued appropriately, overturn rates would be far lower.
When the AHIP spring progress report is released, use it as a payer-specific operations benchmark — not just a policy document. Identify which of your top five payers by claim volume are underperforming on standardization and PA volume reduction. Those payers warrant automated PA tracking, not manual follow-up. Every dollar spent on staff manually chasing PA status updates from low-performing payers has a measurable negative ROI when automation can handle that workflow in seconds.
The most consequential vendor announcement of this issue cycle: Waystar launched agentic intelligence within its cloud-native platform in January 2026, and the early results are reshaping how the industry defines “AI in RCM.” The transition from AI as assistant to AI as autonomous operator is no longer theoretical — it is live in production environments handling billions of transactions annually.
Waystar’s AltitudeAI engine operates across 7.5 billion annual transactions. Agentic AI agents execute multi-step RCM tasks — eligibility verification through claim scrubbing through denial prediction through appeal filing — with human oversight reserved only for flagged exceptions. The platform is also the first to address “silent denials”: payer payment take-backs that bypass standard notification workflows and quietly erode collections without triggering normal denial alerts.
The contrast between AI potential and AI penetration is the defining tension of 2026 RCM. 63% of providers have introduced AI in some capacity, but only 15% have fully integrated AI into standard RCM operations. U.S. healthcare organizations lose over $262 billion annually to RCM inefficiencies — claim denials, undercoding, delayed follow-up, and manual workflows. Estimates project $18.4 billion in annual savings are available with full automation.
The primary barriers: 50% of healthcare leaders cite data privacy and security as the biggest concern; 41% say they find it difficult to fully trust AI accuracy. Both barriers are addressable through vendor contracting (BAA language, audit logs) and phased deployment with measurable accuracy KPIs.
If your practice has more than 200 Medicare Advantage or commercial denials per month and is still manually working denial queues, the ROI case for agentic AI is no longer speculative — it is documented. Request demos from Waystar, AKASA, and Commure with a specific ask: “Show me your denial resolution rate for practices at our claim volume and payer mix.” Vendors who cannot produce that data should not move forward in your evaluation.
Two major coding developments require immediate attention from billing teams this week: the April 1 ICD-10-CM instructional note changes (now in effect) and the most sweeping cardiology CPT restructuring in years, which has been live since January 1 but is generating compliance issues in practice this quarter.
No ICD-10-CM codes were added, deleted, or revised — but 14 chapters received instructional note revisions with real billing consequences. The critical change: multiple Excludes1 notes have been converted to Excludes2, meaning code pairs that were previously prohibited can now be legitimately used together when both conditions coexist. Chapter 2 (Neoplasms) has the most practice-impacting conversions, including under D18 and D49. Coders must update their reference materials and EHR superbill code pair logic.
Cardiology billing has undergone the most significant code restructuring of any specialty this year. Practices that have not fully audited their cardiology superbills against the 2026 CPT book are filing claims that will be denied or flagged for audit.
H.R. 1 (“One Big Beautiful Bill Act”) provisions include a 2.5% reimbursement increase for Chronic Care Management (CCM), Advanced Primary Care Management (APCM), and Remote Physiologic Monitoring (RPM) services, with an additional 1.24% increase for providers participating in Alternative Payment Models. For practices with a chronic disease panel, enrolling eligible patients in CCM generates $280–$420 per enrolled patient per year with existing clinical staff.
Cardiology practices submitting claims with deleted PCI codes (92921, 92925, 92929, 92934, 92938, 92944) are generating preventable denials on every claim. These codes have been invalid since January 1, 2026. If your billing system or EHR superbill has not been updated, run an immediate audit on all cardiology claims submitted in Q1 2026 and resubmit any using deleted codes with corrected CPT assignments before payer timely filing limits expire.
The performance gap between high-performing and average-performing practices is not narrowing in 2026 — it is widening. Automation-native practices are hitting Days in A/R below 25 days while the industry median sits at 33–42 days depending on specialty. That 10-to-17-day differential represents weeks of cash flow advantage and compounding on every dollar of revenue collected.
| Metric | Industry Average | Best Practice Target | Top Performer |
|---|---|---|---|
| Days in A/R | 33–42 days | <30 days | ~25 days |
| Denial Rate | 6–13% | <5% | <3% |
| Clean Claims Rate | ~82–85% | 95%+ | 98%+ |
| First-Pass Resolution | ~70% | 90%+ | 95%+ |
| Patient Collection Rate | 55–65% | >80% | >90% |
CMS’s 2026 PFS conversion factor rebalancing creates a direct, computable revenue velocity lever for independent office-based practices: independent office-based service payments rose approximately 4% while facility-based physician payments fell approximately 7%. The net differential is an ~11 percentage point swing between service settings. For a practice generating $2 million in annual Medicare/MA revenue, accurate site-of-service coding is worth approximately $220,000 in relative annual positioning against facility-based competitors.
If your Days in A/R exceed 40 days, you have a specific, locatable bottleneck. Map your denial pipeline by age bracket (0–30 days, 31–60 days, 61–90 days, 90+ days) this week. The highest-density bucket reveals where the bottleneck is: 31–60 day concentration indicates slow charge entry or eligibility failure at front-end; 61–90 day concentration indicates manual denial follow-up lag; 90+ day concentration indicates write-off risk that requires immediate human intervention before timely filing limits expire.
The 2026 KLAS Research rankings released in February solidified what the market has been signaling: RCM technology is consolidating around a smaller number of high-performing, integrated platforms. Point solutions without AI-native capabilities are losing ground to comprehensive RCM platforms with embedded automation.
R1 RCM was awarded Best in KLAS across multiple categories for the seventh consecutive year, bringing its total to 18 KLAS awards since 2020. 2026 Best in KLAS categories for R1 include: Extended Business Office: Small (<200 beds), Government Reimbursement Services, and Underpayment Recovery Services. athenahealth achieved the #1 Best in KLAS ranking in five categories for 2026, maintaining its position as the leading integrated EHR/RCM platform for ambulatory and independent practices.
| Layer | Technology | Key Vendors |
|---|---|---|
| Generative AI | Autonomous coding, denial appeal drafting, clinical documentation analysis | AKASA, CodaMetrix, Commure |
| AI / ML | Predictive denial prevention, payer-specific claim scoring, eligibility risk flags | Waystar (AltitudeAI), Experian Health, Aspirion, Innovaccer |
| RPA | Eligibility verification, claim status checks, ERA reconciliation, payment posting | Waystar, Quadax, athenahealth, R1 RCM |
| EHR / PM Integration | FHIR APIs, charge capture, real-time documentation, superbill automation | Epic, athenahealth, Oracle Health, ModMed |
74% of U.S. hospitals have deployed some form of RCM automation. The market has moved past early adoption. Vendors without AI-native capabilities are being displaced. The 2026 technology purchasing pattern: practices and health systems are consolidating vendor relationships around integrated, API-first, automation-native RCM platforms rather than adding point solutions for individual RCM tasks.
If your practice is running RCM across three or more separate point solutions — a standalone eligibility tool, a separate billing platform, and a third-party denial management vendor — you are paying a hidden coordination overhead at every integration handoff. Each handoff is a latency point, a data gap risk, and a denial opportunity. The 2026 technology playbook is consolidation, not proliferation. The practices pulling ahead on Days in A/R are not the ones with more tools — they are the ones with fewer, better-integrated ones.
Two compliance clocks are running simultaneously this week — one that has already started billing practices for non-compliance, and one with a six-month runway that requires planning to begin now.
CMS granted a 90-day enforcement grace period for the upgraded 2026 hospital price transparency requirements, which technically took effect January 1. That grace period expired April 1, 2026. Penalties are now active for hospitals — and for practices billing hospital outpatient services, patient-facing price data is now being published under stricter accuracy standards that affect financial counseling conversations at the point of service.
| Hospital Size | Daily Penalty |
|---|---|
| 30 or fewer beds | Up to $300/day |
| 31–550 beds ($10/bed/day) | Up to $5,500/day (300-bed example: $3,000/day) |
| Over 550 beds | $5,500/day |
The April 2 CMS final rule makes MA marketing and communications changes effective October 1, 2026 — six months from now. Practices with MA plan contracts, network agreements, or patient-facing MA plan enrollment communications must begin compliance planning now. Specific rules eliminate several 2023 enrollment safeguards, change how plan comparisons are communicated, and revise third-party marketing organization requirements.
With 14 chapters of ICD-10-CM now reflecting new Excludes2 code pair permissions (previously Excludes1), billing software and EHR superbill configurations that block the now-permitted code pairs will generate incorrect validation errors. Coding software vendors (including AAPC Codify and OptumCoding) updated automatically on April 1 — but internal EHR superbills and custom claim edit rules may require manual update.
Hospital price transparency violations are accumulating daily at up to $5,500/day for large facilities. If your organization bills hospital outpatient services and the machine-readable file has not been updated to include median allowed amounts, 10th/90th percentile data, and Type 2 NPIs, the financial exposure grows with every day of delay. The enforcement grace period is over.
CMS’s 2026 PFS rebalancing has created what may be the most durable structural revenue advantage for independent practices in a decade. While hospital-affiliated facility-based physician payments fell approximately 7%, independent office-based service payments rose approximately 4%. The 11-point differential is not a timing artifact — it is a deliberate CMS policy signal: the payment system rewards care delivered in independent physician offices over hospital outpatient settings.
| RCM Metric | Independent Practice Avg | Industry Best Practice | Priority If Below Target |
|---|---|---|---|
| Days in A/R | 38–45 days | <30 days | Eligibility automation, charge entry speed |
| Denial Rate | 8–12% | <5% | Payer-specific edit rules, claim scrubbing |
| CCM/RPM Enrollment | <15% of eligible | >40% of eligible | Use April CCM code & H.R. 1 reimbursement bump now |
| Patient Collection Rate | 55–65% | >80% | Point-of-service collection, payment plans |
| Clean Claims Rate | 82–88% | >95% | Pre-submission AI claim scrubbing |
| Site-of-Service Accuracy | Unknown for most | 100% accurate | Audit facility vs. non-facility claim split immediately |
Independent practices sustaining profitability in 2026 margin compression share three operational traits: (1) fully automated eligibility verification — real-time, not manual at check-in; (2) an active CCM/RPM program capturing chronic care billing codes across their chronic disease panel; and (3) site-of-service billing accuracy — every office-based encounter correctly coded as non-facility. The AMA notes that a 1% improvement in first-pass resolution rate is worth approximately $30,000 per year for a three-physician practice.
If your practice bills any services deliverable in either an office or hospital outpatient setting, run a facility vs. non-facility claim split audit on your top 20 procedure codes this week. Every encounter legitimately reclassifiable from facility to non-facility is now worth approximately 11% more under 2026 CMS payment rules. For a practice with $1.5M in facility-coded Medicare revenue that qualifies as non-facility, that audit is worth approximately $165,000 in annual recoverable revenue.
This week’s specialty developments span the full reimbursement spectrum — from primary care practices gaining new CCM revenue to oncologists navigating the steepest Medicare payment cuts in recent years. Each specialty section includes at least one data point and one immediate action.
| Specialty | Key Update | Revenue Impact | Action |
|---|---|---|---|
| Primary Care | H.R. 1 delivers 2.5% CCM/APCM/RPM reimbursement boost + 1.24% for APM participants; expanded CCM/PCM/TCM/RPM codes now active | +$280–$420 per enrolled chronic care patient per year | Identify all eligible chronic disease patients not enrolled in CCM; enroll this month to capture H.R. 1 bump from April forward |
| Cardiology | 6 PCI codes deleted (92921, 92925, 92929, 92934, 92938, 92944); 46 new LER codes (37254–37299); new billable AI cardiac CT diagnostic CPT category; remote monitoring code updates | Miscoding risk on every deleted-code claim; new AI CT billing revenue opportunity | Audit all cardiology claims Q1 2026 for deleted PCI codes; add AI cardiac CT CPT to superbill; review LER procedure mapping |
| Orthopedics | TEAM (Transforming Episode Accountability) model mandatory Jan. 1, 2026 for hospital-affiliated practices covering 5 major procedures (joint replacements, spinal fusions); CMS applied −2.5% efficiency adjustment; site-neutral payment expansion ongoing | Facility-based orthopedics: TEAM bundling changes episode accounting; −2.5% efficiency cut applies broadly | Independent ortho practices: optimize office-based billing for the +4% CMS advantage; TEAM participants: model episode financials under 2026 bundled payment rates now |
| Oncology | 37% of oncologists estimated to face 10–20% Medicare pay cuts under 2026 PFS; radiation oncology and diagnostic imaging billing restructured; procedure & imaging code changes affect specialties billing both categories | Significant revenue exposure; radiation oncology especially affected by restructured codes | Validate all radiation therapy and diagnostic imaging CPT codes against 2026 PFS final rule; explore CCM billing for oncology care management as revenue offset |
| Radiology | Site-neutral payment policies affect hospital-based radiology departments; diagnostic imaging code restructuring under 2026 PFS changes; CY 2026 OPPS final rule alters hospital outpatient radiology payment rates | Hospital outpatient radiology revenue at risk under site-neutral rules | Review CMS 2026 OPPS radiology payment tables; verify all imaging codes in billing system reflect 2026 PFS final values |
| Mental Health | Telehealth parity extensions continued through 2026; expanded reimbursement for Collaborative Care Model (CoCM); E/M integration billing for behavioral health continues | Telehealth billing remains strong; new CoCM codes add revenue for integrated care practices | Verify telehealth billing compliance under 2026 parity rules; evaluate Collaborative Care Model CPT billing if not yet implemented |
| Gastroenterology | GI endoscopy unbundling modifier rules updated in 2026; new surveillance colonoscopy codes in effect; bundling edit changes affect GI endoscopy procedure pairs | Billing accuracy is critical post-unbundling changes; incorrect modifier use triggers systematic denials | Audit all GI endoscopy claims for modifier compliance; validate surveillance colonoscopy codes against updated 2026 CPT guidance |
The 2026 specialty landscape is bifurcating sharply. Specialties with strong procedural and technology billing (cardiology’s new AI CT codes, primary care’s CCM expansion) are gaining incremental revenue pathways. Specialties with high procedural Medicare volume (oncology, facility-based orthopedics, radiology) are absorbing structural payment cuts. The common denominator for all specialties: billing accuracy and code update compliance determine whether practices capture available revenue or surrender it to preventable denials.
Tied directly to this issue’s content — prioritized by urgency and revenue impact: